Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00949078 · ClinicalTrials.gov registry record · Phase 2
Omalizumab in the Treatment of Peanut Allergy
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00949078: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT00949078 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00949078, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with omalizumab (Xolair, anti-IgE) can eliminate or reduce symptoms of peanut allergy.
Interventions
- DRUG omalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00949078
The ClinicalTrials.gov registry entry for NCT00949078 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which omalizumab is the first listed.
NCT00949078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00949078 about?
NCT00949078 is a clinical study titled "Omalizumab in the Treatment of Peanut Allergy". The purpose of this study is to determine if treatment with omalizumab (Xolair, anti-IgE) can eliminate or reduce symptoms of peanut allergy.
What is the current status of trial NCT00949078?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2009-07. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00949078?
The interventions under investigation include: omalizumab (DRUG).
Who is sponsoring clinical trial NCT00949078?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.